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Abstract 
The gallbladder (GB) is an assistant organ of the digestive system, It is  located under the liver 
and attached to the biliary system, And it is responsible for controlling release of bile and the storage. 
Gallstone disease a major health problem worldwide. In 10–15% of adults contain gallstone disease. 
This study (case control) consists of  one hundred sixty (160) patients are included in this study 
randomly selected  and consisted of 130 females and 30 males. All patients are examined 24 hr. Before 
operation, Intra operatively and 24hr post operatively. Decreased gallbladder motility and the decrease 
of cholesterol 7 –alpha hydroxylase activity, which regulate the novo bile salt synthesis. The rate-
limiting step of bile acid synthesis is acting between the liver-specific CYP 7A1 (CYP450). Thus, 
Alteration in CYP gene control also has an impact on bile acid synthesis and lipid metabolism. 
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ةصلاخلا 
ةرارملا (GB) وى زايجلا دعاسملا نم ،يمضيلا زايجلا عقت يىو تحت ىمع قمعتو دبكلا ماظن ،يوارفصلا  اينأونع ةلوؤسم 
يف مكحتلا قلاطإ ءارفصلا نيزختلاو. ضرم ةوصح ةريبك ةيحص ةمكشم ملاعلا ءاحنأ عيمج يف. يف 10-15نيغلابلا نم ٪ ءاوتحا 
ضرم ةوصح. ةساردلا هذى (ةبقارم ةلاح) نم نوكتيو 160 (160) تممشو ىضرملا يف ةساردلا هذى فلأتيو ،ايئاوشع اىرايتخا مت نم 
130 و ثانلإا نم 30 مروكذلا ن. صحف متيو ىضرملا عيمج 24 ةعاس. ،ةيممعلا لبق لخاد ةحارجلا دعبو ةحارجلا 24hr. ضافخنا 
ةكرحلا ةرارملا ضافخناو لورتسلوكلا 7 -alpha طاشنلا ،زلايسكورديى مظنت يتلا وفون فيلوت حمملا ءارفصلا. ةوطخ لدعم نم دحلاو 
نم  يرارملا ضماحلا بيكرت فرصتي نيب 7A1 CYP دبكلا نيعم (CYP450). ،اذكىو تلايدعتلاو ةرطيسلا يف تانيجلا CYP  اضيأ
ريثأت ول ىمع  يرارملا ضماحلا بيكرت  نوىدمل يئاذغلا ليثمتلاو. 
 
ممكلا:ةيحاتفملا تا ةرارملا (GB)، ضرم ةوصحلا (GD)، CYP 7A1. 
 
Introduction 
The gallbladder (GB) is an assistant organ of the digestive system, It is  
located under the liver and attached to the biliary system, And it is responsible for 
controlling release of bile and the storage (Kennth et al., 2014). Gallstone disease a 
major health problem worldwide (Abeysuriya et al., 2010). In world 10–15% of 
adults contain gallstone disease (Ansaloni, 2016)). cholelithiasis is referred to present 
of stones in the gallbladder (James et al., 2011). Cholelithiasis or Gallstone disease 
(GD), is one of the general gastrointestinal diseases (Sun et al., 2009). A gallstone is a 
stone consist of  in the gallbladder out of bile components (Stinton et al., 2012). Most  
people with gallstones (about 80%) don’t have  symptoms  (Lee et al., 2015). Occurs 
each year in 1–4% of those with gallstones, known as biliary colic, Inflammation of 
the pancreas,  gallbladder and liver  consider the complications of gallstones (3). 
Gallstones may be suspected based on signs (3). Diabetes, contraceptive pill, 
pregnancy, a family history of gallstones, obesity, or rapid weight loss are consider 
risk factors for gallstones. It is asymptomatic, even for years. These gallstones do not 
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require treatment are called "silent stones" (Bethesda et al., 2007; Heuman et al., 
2010; https://en.wikipedia.org/wiki/Gallstone - cite_note-Acalovschi2003-10). Other 
complications; gallstones may  the gallbladder into adherent abdomen potentially, in 
cases of chronic inflammation, causing an obstruction termed gallstone ileus 
(Acalovschi et al., 2003). There may be several reasons of Gallstones, including: 
weight, genes, Problems with gall bladder or Diet (Derrer et al., 2016). Gallstone  is 
classified as cholesterol, pigment and mixed stones, Based on their chemical 
composition (Grunhage et al., 2006; Gurusamy et al., 2007; Sikkandar et al., 2011). 
Deoxycholic acid did not prevent HMG CoA reductase action (Williams et al., 2008).  
 
Aims of the study  
1. To investigate the association between serum bile acid and cholesterol 7-alpha 
hydroxylase and the development of gallstone disease. 
2. Evaluate the serum insulin changes and its effect to gallstone formation. 
3. The determination of serum superoxide dismutase changes in patients with 
gallstone. 
 
Patient and  Materials  
After approval of the study by the ethical committee of college of medicine 
and consent of patients  an explained to them. This prospective study is carried out in 
Al-Hilla general teaching hospital  lasted from November (2015) to May (2016). This 
study (case control) consists of  one hundred sixty (160) patients are included in this 
study randomly selected  and consisted of 130 females and 30 males. All patients are 
examined 24hr. before operation, Intra operatively and 24hr post operatively. Their 
ages  are  between  20-70 years for females and as well as 20-70 years for male 
patients. Those patients are diagnosed by specialist doctors as uncomplicated, 
symptomatic gallstones (cholelithiasis), who underwent elective laparoscopic 
cholecystectomy. 
 
3.2.4.1:Measurement of CYP 7A1 level (Catalog No: E-EL-H208) 
Principle: 
This ELISA kit uses Sandwich-ELISA as the method. Only those wells that 
contain CYP7A1, biotinylated detection antibody and Avidin-HRP conjugate will 
appear blue in color. The micro ELISA plate provided in this kit has been pre-coated 
with an antibody specific to CYP7A1.The enzyme-substrate reaction is terminated by 
the addition of a sulphuric acid solution and the color turns yellow. Then a 
biotinylated detection antibody specific for CYP7A1 and Avidin-Horseradish 
Peroxidase (HRP) conjugate is added to each micro plate successively and incubated. 
Standards or samples are added to the appropriate micro ELISA plate wells and 
combined with the specific antibody. Free components are washed away. The OD 
value is proportional to the concentration of CYP7A1. The substrate solution is added 
to each well. The optical density (OD) is measured spectrophotometrically at a 
wavelength of 450 nm ± 2 nm. You can calculate the concentration of CYP7A1 in the 
samples by comparing the OD of the samples to the standard curve. 
Assay procedure Centrifuge the sample again after thawing before the assay. Bring 
all reagents and samples to room temperature before use. Avoid foaming. It’s 
recommended that all samples and standards be assayed in duplicate. All the reagents 
should be mixed thoroughly by gently swirling before pipette.  
1. Add Sample: Add 100μL of Standard, Blank, or Sample per. The blank well is 
added with Reference Standard & Sample diluent. Solutions are added to the 
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bottom of the micro ELISA plate well. Cover the plate with sealer we provided. 
Incubate for 90 minutes at 37℃. A void inside wall touching and foaming as 
possible. Mix it gently 
2. Biotinylated Detection Ab: don't wash, Remove the liquid of each. Immediately 
add 100μL of Biotinylated Detection Ab working solution to each well. Cover with 
the Plate sealer. Gently tap the plate to ensure thorough mixing. Incubate for 1 
hour at 37°C. 
3. Wash: Wash by filling each with Wash Buffer (approximately 350μL) (a squirt 
bottle, Complete removal of liquid at each step is essential. After the last wash, 
manifold dispenser, multi-channel pipette, or automated washer are needed). 
Aspirate each well and wash, repeating the process three times. 
4. HRP Conjugate: Incubate for 30 minutes at 37°C., Add 100μL of HRP Conjugate 
working solution to each well.  
5. Wash: Repeat the wash process about five times as conducted in step 3.  
6. Substrate: Add 90μL of Substrate Solution to each well. Incubate for about 15 
minutes at 37°C. Protect the plate from light. When apparent gradient appeared in 
standard wells, Cover with a new Plate sealer. The reaction time can be shortened 
or extended according to the actual color change, but not more than 30minutes. 
7. Stop: The order to add stop solution should be the same as the substrate solution. 
Add 50μLof Stop Solution to each well. Then, the color turns to yellow 
immediately.  
 8. OD Measurement: Determine the optical density (OD value) of each preheat the 
instrument, well at once and set the testing parameters. Using a micro-plate reader 
at 450 nm.  
9. After experimenting, until their expiry. Put all the unused reagents back into the 
refrigerator according to the specified storage temperature respectively. 
 Important note: 1. ELISA Plate: The just opened ELISA Plate may appear water-
like substance. 
2. Add Sample: The interval of sample adding between the first well and the last well 
should not be too long, which will significantly affect the experiment’s accuracy 
and repeatability, otherwise will cause different pre-incubation time.  
3. Incubation: proper adhesion of plate sealers during incubation steps is necessary, 
To prevent evaporation and ensure accurate results. Do not let the strips dry at any 
time during the assay.  
4. Washing: Insufficient washing will result in poor precision and falsely elevated 
absorbance readings. Residual liquid in the reaction wells should be patted dry 
against the absorbent paper in the washing process. The wash procedure is critical. 
5. Reagent Preparation: As the volume of Concentrated Biotinylated Detection Ab 
and Concentrated HRP Conjugate is very small, To ensure that pipette are 
calibrated is minimize imprecision caused by pipette. Liquid may adhere to the 
tube wall or the tube cap when being transported, It is recommended to suck more 
than 10μL for once pipette. Please pipette the solution for 4-5 times before pipette.. 
Do not reuse the standard solution, working solution of Detection Ab and HRP 
Conjugate, which have been diluted, Please carefully reconstitute Standards, 
working solutions of Detection Ab and HRP Conjugate according to the 
instructions.  
6. Reaction Time Control: Please mange reaction time strictly following this product 
description. 
7. Substrate: Please protect it from light, Substrate Solution is easily contaminated.  
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8. Stop Solution: As it is an acid solution, please pay attention to the protection of 
your face, eyes, hands, and clothes when using this solution. 
9. Mixing: You’d better use micro-oscillator at the lowest frequency, you can knock 
the ELISA plate frame gently with your finger before reaction., as sufficient and 
gentle mixing is particularly important to reaction result.  
10. Security: please perform, Please wear lab coats and latex gloves.  
11. Washing buffer and stop solution can be an exception) (Do not use components 
from different batches of kit). 
12. To avoid cross-contamination, between reagent adding and  sample adding, 
change pipette tips, and between adding of each standard level. Also, use separate 
reservoirs for each reagent. 
 
Result 
4.3.1. Cholesterol 7-alpha hydroxylase (CYP 450)  
 Table (4-8) The cytochrome p450 (CYP 450) level in both patients and control 
groups. It is highly significant lower in patient groups when compared with control 
groups (P<0.01). 
 
Table (4-8): The cytochrome p450 (CYP 450) level in both patients and control 
group. 
Parameter Group mean± SD. P. Value 
Cholesterol 7-alpha 
hydroxylase (µM) 
Patients 15.68±2.69 
0.001** 
Control 21.87±1.63 
** highly  significant differences at P<0.01 
 
Discussion 
Cholesterol 7-alpha hydroxylase (CYP 450)   
Table (4-8) shows the cytochrome p450 (CYP 450) level in both patients and 
control groups. It is highly significant lower in patient groups when compared with 
control groups (P<0.01). And these results are agreeing with another study done by 
(G.Schulthess et al., 2000). 
 Decreased gallbladder motility and the decrease of cholesterol 7 –alpha 
hydroxylase activity, which regulate de novo bile salt synthesis (Einarsson et al., 
1985). Additionally to this central role of hepatic CYPs in the handling of 
xenobiotics, the rate-limiting step of bile acid synthesis is acting between the liver-
specific CYP 7A1 (CYP450). Thus, Alteration in CYP gene control also has an 
impact on lipid metabolism and bile acid synthesis (Aleksunes et al., 2012). CYP7A1 
and HMGR expression levels were high, resulting in increase synthesis of hepatic 
cholesterol and bile acids, Also HDL metabolism was impaired (Akiyama et al., 
2000; Shih et al., 2001). In contrast, given of fibrates to humans does inhibit CYP7A1 
expression, resulting in an elevated risk for gallstone formation (Stahlberg et al., 
1995; Caroli –Bosc et al., 2001). 
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